

Yasuhiro Fujiwara

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2983752/yasuhiro-fujiwara-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

223
papers

6,289
citations

38
h-index

71
g-index

225
ext. papers

7,180
ext. citations

5.1
avg, IF

5.11
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 223 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5132-9 ^{2.2} | 2.2 | 1150 |
| 222 | Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 793-805 | 4.4 | 205 |
| 221 | Novel combination of serum microRNA for detecting breast cancer in the early stage. <i>Cancer Science</i> , 2016 , 107, 326-34 | 6.9 | 197 |
| 220 | Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. <i>Lancet Oncology</i> , 2017 , 18, 1512-1522 | 21.7 | 195 |
| 219 | ⁶⁴ Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1869-75 | 8.9 | 178 |
| 218 | Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2006 , 99, 9-17 | 4.4 | 118 |
| 217 | Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. <i>Cancer Science</i> , 2019 , 110, 1480-1490 | 6.9 | 117 |
| 216 | Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. <i>Supportive Care in Cancer</i> , 2016 , 24, 447-455 | 3.9 | 114 |
| 215 | Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. <i>Journal of Neuro-Oncology</i> , 2009 , 93, 205-12 | 4.8 | 107 |
| 214 | Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. <i>Clinical Cancer Research</i> , 2012 , 18, 4841-9 | 12.9 | 102 |
| 213 | Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. <i>Human Pathology</i> , 2004 , 35, 1537-42 | 3.7 | 97 |
| 212 | Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 188, 571-7 | 3.4 | 93 |
| 211 | Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. <i>Cancer</i> , 2010 , 116, 302-8 | 6.4 | 90 |
| 210 | Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. <i>Cancer Science</i> , 2012 , 103, 1665-71 | 6.9 | 78 |
| 209 | Pharmacokinetics of (glycolate-0,0)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 1989 , 23, 243-6 | 3.5 | 75 |
| 208 | Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. <i>ESMO Open</i> , 2017 , 2, e000150 | 6 | 73 |
| 207 | Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 127-36 | 4.4 | 73 |

| | | | |
|-----|--|-----|----|
| 206 | Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 132-8 | 4.2 | 70 |
| 205 | The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. <i>Breast</i> , 2012 , 21, 289-95 | 3.6 | 69 |
| 204 | Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. <i>Japanese Journal of Cancer Research</i> , 1988 , 79, 301-4 | | 69 |
| 203 | Determinants of drug response in a cisplatin-resistant human lung cancer cell line. <i>Japanese Journal of Cancer Research</i> , 1990 , 81, 527-35 | | 65 |
| 202 | Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. <i>Japanese Journal of Cancer Research</i> , 1997 , 88, 218-23 | | 64 |
| 201 | N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. <i>Cancer Science</i> , 2008 , 99, 1611-9 | 6.9 | 64 |
| 200 | (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. <i>EJNMMI Research</i> , 2015 , 5, 8 | 3.6 | 62 |
| 199 | A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. <i>British Journal of Cancer</i> , 2019 , 120, 475-480 | 8.7 | 58 |
| 198 | Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. <i>Cancer Science</i> , 2008 , 99, 1237-42 | 6.9 | 57 |
| 197 | Characterization of an etoposide-resistant human small-cell lung cancer cell line. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 26, 313-7 | 3.5 | 56 |
| 196 | Physicians' knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists. <i>Breast Cancer</i> , 2013 , 20, 230-40 | 3.4 | 55 |
| 195 | In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay. <i>Cancer Chemotherapy and Pharmacology</i> , 1988 , 22, 246-50 | 3.5 | 53 |
| 194 | Feasibility and usefulness of the Distress Screening Program in Ambulatory Care in clinical oncology practice. <i>Psycho-Oncology</i> , 2010 , 19, 718-25 | 3.9 | 51 |
| 193 | Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 401-9 | 4.4 | 50 |
| 192 | High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. <i>Biomedical Applications</i> , 1995 , 670, 309-16 | | 47 |
| 191 | Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. <i>Japanese Journal of Cancer Research</i> , 1994 , 85, 1240-6 | | 46 |
| 190 | Development and validation of diagnostic prediction model for solitary pulmonary nodules. <i>Respirology</i> , 2007 , 12, 856-62 | 3.6 | 45 |
| 189 | The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 100, 412-6 | 4.9 | 43 |

| | | | |
|-----|---|------|----|
| 188 | The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. <i>Japanese Journal of Cancer Research</i> , 1997 , 88, 1211-7 | | 42 |
| 187 | Quantitative assessment of appearance changes and related distress in cancer patients. <i>Psycho-Oncology</i> , 2013 , 22, 2140-7 | 3.9 | 39 |
| 186 | The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). <i>Japanese Journal of Cancer Research</i> , 1993 , 84, 83-92 | | 38 |
| 185 | 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. <i>Breast</i> , 2009 , 18, 171-4 | 3.6 | 37 |
| 184 | Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. <i>European Urology</i> , 2007 , 52, 1115-22 | 10.2 | 36 |
| 183 | First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 829-38 | 4.4 | 35 |
| 182 | Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. <i>Oncologist</i> , 2009 , 14, 752-9 | 5.7 | 34 |
| 181 | Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. <i>International Journal of Cancer</i> , 2000 , 86, 95-100 | 7.5 | 34 |
| 180 | The notorious "drug lag" for oncology drugs in Japan. <i>Investigational New Drugs</i> , 2011 , 29, 706-12 | 4.3 | 33 |
| 179 | Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. <i>Pathology Research and Practice</i> , 2006 , 202, 705-12 | 3.4 | 33 |
| 178 | No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. <i>Japanese Journal of Cancer Research</i> , 1996 , 87, 1280-7 | | 33 |
| 177 | Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. <i>Molecular Cancer</i> , 2016 , 15, 73 | 42.1 | 32 |
| 176 | Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging. <i>Scientific Reports</i> , 2016 , 6, 23749 | 4.9 | 32 |
| 175 | Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. <i>Breast Cancer</i> , 2015 , 22, 141-52 | 3.4 | 31 |
| 174 | Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. <i>Japanese Journal of Cancer Research</i> , 1991 , 82, 747-51 | | 31 |
| 173 | Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 457-65 | 3.5 | 30 |
| 172 | Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 48-52 | 4.2 | 29 |
| 171 | Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group. <i>Japanese Journal of Clinical Oncology</i> , 2006 , 36, 777-85 | 2.8 | 29 |

| | | | |
|-----|---|------|----|
| 170 | Immunohistochemical profiles of brain metastases from breast cancer. <i>Journal of Neuro-Oncology</i> , 2008 , 90, 223-8 | 4.8 | 29 |
| 169 | Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. <i>Medical Oncology</i> , 2009 , 26, 344-9 | 3.7 | 28 |
| 168 | Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 48, 42-6 | 3.5 | 28 |
| 167 | Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer. <i>Cancer Letters</i> , 2000 , 156, 93-9 | 9.9 | 27 |
| 166 | Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. <i>Biological and Pharmaceutical Bulletin</i> , 2012 , 35, 717-24 | 2.3 | 26 |
| 165 | Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC). <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 42, 145-55 | 7 | 26 |
| 164 | Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005 , 89, 237-41 | 4.4 | 26 |
| 163 | Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 1179-1186 | 3.5 | 25 |
| 162 | A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2012 , 125, 307-11 | 4.9 | 25 |
| 161 | Contrasting prognostic implications of platelet-derived growth factor receptor- β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2841-50 | 3.1 | 25 |
| 160 | Evolution of frameworks for expediting access to new drugs in Japan. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 293-4 | 64.1 | 25 |
| 159 | Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. <i>Supportive Care in Cancer</i> , 2018 , 26, 2161-2166 | 3.9 | 24 |
| 158 | PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. <i>Cancer Science</i> , 2018 , 109, 2558-2566 | 6.9 | 23 |
| 157 | Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995 , 121, 729-38 | 4.9 | 23 |
| 156 | A phase I study of farletuzumab, a humanized anti-folate receptor β monoclonal antibody, in patients with solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 332-40 | 4.3 | 22 |
| 155 | TERT promoter hotspot mutations in breast cancer. <i>Breast Cancer</i> , 2018 , 25, 292-296 | 3.4 | 22 |
| 154 | Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. <i>Journal of Orthopaedic Science</i> , 2010 , 15, 654-60 | 1.6 | 21 |
| 153 | Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. <i>Breast</i> , 2007 , 16, 482-8 | 3.6 | 21 |

| | | | |
|-----|--|-----|----|
| 152 | Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan). <i>Journal of Cancer Research and Clinical Oncology</i> , 1987 , 113, 563-6 | 4.9 | 21 |
| 151 | Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. <i>Drug Metabolism and Pharmacokinetics</i> , 2019 , 34, 209-216 | 2.2 | 20 |
| 150 | Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy. <i>Breast</i> , 2013 , 22, 263-7 | 3.6 | 20 |
| 149 | Efficacy of taxane regimens in patients with metastatic angiosarcoma. <i>European Journal of Dermatology</i> , 2011 , 21, 539-45 | 0.8 | 20 |
| 148 | Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. <i>Journal of Proteome Research</i> , 2009 , 8, 457-62 | 5.6 | 20 |
| 147 | Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 119, 28-34 | 4.9 | 20 |
| 146 | Cis-diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells. <i>International Journal of Cancer</i> , 1993 , 55, 616-22 | 7.5 | 20 |
| 145 | Molecular imaging using PET for breast cancer. <i>Breast Cancer</i> , 2016 , 23, 24-32 | 3.4 | 19 |
| 144 | A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 621-8 | 4.2 | 19 |
| 143 | Impact of recent parity on histopathological tumor features and breast cancer outcome in premenopausal Japanese women. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 941-50 | 4.4 | 19 |
| 142 | Immunohistochemical profile for unknown primary adenocarcinoma. <i>PLoS ONE</i> , 2012 , 7, e31181 | 3.7 | 19 |
| 141 | Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. <i>Oncologist</i> , 2016 , 21, 508-13 | 5.7 | 19 |
| 140 | Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 307-13 | 4.4 | 18 |
| 139 | Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. <i>International Journal of Clinical Oncology</i> , 2006 , 11, 421-5 | 4.2 | 18 |
| 138 | The expression and clinical significance of ribophorin II (RPN2) in human breast cancer. <i>Pathology International</i> , 2015 , 65, 301-8 | 1.8 | 17 |
| 137 | Nucleostemin expression in invasive breast cancer. <i>BMC Cancer</i> , 2014 , 14, 215 | 4.8 | 17 |
| 136 | Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. <i>Scientific Reports</i> , 2017 , 7, 12622 | 4.9 | 16 |
| 135 | Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer. <i>Breast Cancer</i> , 2013 , 20, 145-51 | 3.4 | 16 |

| | | | |
|-----|---|------|----|
| 134 | Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 337-42 | 3.5 | 16 |
| 133 | Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. <i>Journal of Surgical Oncology</i> , 2010 , 101, 222-7 | 2.8 | 16 |
| 132 | Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. <i>Breast Journal</i> , 2005 , 11, 311-6 | 1.2 | 16 |
| 131 | Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance. <i>International Journal of Cancer</i> , 1991 , 48, 931-7 | 7.5 | 16 |
| 130 | Japanese universal health care faces a crisis in cancer treatment. <i>Lancet Oncology, The</i> , 2015 , 16, 251-2 | 21.7 | 15 |
| 129 | Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2007 , 37, 1-8 | 2.8 | 15 |
| 128 | Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. <i>Breast Cancer</i> , 2019 , 26, 492-498 | 3.4 | 14 |
| 127 | Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor. <i>Oncology</i> , 2018 , 94, 340-344 | 3.6 | 14 |
| 126 | Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011 , 159, 394-8 | 2.4 | 14 |
| 125 | Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 551-7 | 4.9 | 14 |
| 124 | Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 558-566 | 2.2 | 14 |
| 123 | Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. <i>Cancer Science</i> , 2017 , 108, 1520-1529 | 6.9 | 13 |
| 122 | Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>Cancer Science</i> , 2017 , 108, 987-994 | 6.9 | 13 |
| 121 | Prognostic factors in young Japanese women with breast cancer: prognostic value of age at diagnosis. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 180-9 | 2.8 | 13 |
| 120 | MiR-1285-5p/TMEM194A axis affects cell proliferation in breast cancer. <i>Cancer Science</i> , 2020 , 111, 395-405 | 4.5 | 13 |
| 119 | A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. <i>European Journal of Cancer</i> , 2019 , 109, 84-91 | 7.5 | 12 |
| 118 | Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015 , 45, 12-8 | 2.8 | 12 |
| 117 | Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study. <i>British Journal of Pharmacology</i> , 2018 , 175, 29-37 | 8.6 | 12 |

| | | | |
|-----|--|-----|----|
| 116 | Visualization of HER2-specific breast cancer intratumoral heterogeneity using Cu-DOTA-trastuzumab PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2146-2147 | 8.8 | 12 |
| 115 | Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 484-90 | 2.8 | 12 |
| 114 | Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. <i>Medical Oncology</i> , 2007 , 24, 425-30 | 3.7 | 12 |
| 113 | ZK1, a novel Krüppel-type zinc finger gene, is induced following exposure to ionizing radiation and enhances apoptotic cell death on hematopoietic cells. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 249, 595-600 | 3.4 | 12 |
| 112 | Perception and needs of reproductive specialists with regard to fertility preservation of young breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2015 , 20, 82-9 | 4.2 | 11 |
| 111 | Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 443-8 | 2.8 | 11 |
| 110 | Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008 , 134, 1199-206 | 4.9 | 11 |
| 109 | Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006 , 132, 635-42 | 4.9 | 11 |
| 108 | Translational studies for target-based drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56 Suppl 1, 90-3 | 3.5 | 11 |
| 107 | Current status of oral anticancer drugs in Japan. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3362-5 | 2.2 | 11 |
| 106 | Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant to cis-diamminedichloroplatinum (II). <i>International Journal of Cancer</i> , 1992 , 50, 438-42 | 7.5 | 11 |
| 105 | Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. <i>BMC Cancer</i> , 2017 , 17, 819 | 4.8 | 10 |
| 104 | Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 127-134 | 3.5 | 10 |
| 103 | Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 1249-57 | 4.9 | 10 |
| 102 | Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapy. <i>Modern Pathology</i> , 2010 , 23, 581-92 | 9.8 | 10 |
| 101 | A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. <i>Cancer</i> , 2005 , 104, 1204-12 | 6.4 | 10 |
| 100 | Expectations of and recommendations for a cancer survivorship guideline in Japan: a literature review of guidelines for cancer survivorship. <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 812-822 | 2.8 | 9 |
| 99 | Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 391-7 | 3.5 | 9 |

| | | | |
|----|---|-----|---|
| 98 | Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. <i>Molecular and Clinical Oncology</i> , 2013 , 1, 995-1001 | 1.6 | 9 |
| 97 | Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. <i>International Journal of Cancer</i> , 1997 , 72, 295-300 | 7.5 | 9 |
| 96 | Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer. <i>Japanese Journal of Cancer Research</i> , 1998 , 89, 855-61 | | 9 |
| 95 | Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 214-218 | 2.8 | 9 |
| 94 | In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 30, 417-22 | 3.5 | 9 |
| 93 | Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. <i>Oncotarget</i> , 2018 , 9, 18540-18547 | 2.3 | 9 |
| 92 | Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 745-52 | 3.5 | 8 |
| 91 | A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1369-74 | 3.5 | 8 |
| 90 | Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. <i>Breast Cancer</i> , 2016 , 23, 624-32 | 3.4 | 7 |
| 89 | A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 590-7 | 4.2 | 7 |
| 88 | Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 49-56 | 3 | 7 |
| 87 | Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. <i>World Journal of Surgery</i> , 2009 , 33, 44-51 | 3.3 | 7 |
| 86 | Primary yolk sac tumor of the omentum: a case report and literature review. <i>Case Reports in Oncology</i> , 2012 , 5, 671-5 | 1 | 7 |
| 85 | Therapy-related acute promyelocytic leukemia caused by hormonal therapy and radiation in a patient with recurrent breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 567-70 | 2.8 | 7 |
| 84 | Clinical efficacy of S-1 in pretreated metastatic breast cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 172-5 | 2.8 | 7 |
| 83 | Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer. <i>Japanese Journal of Cancer Research</i> , 1995 , 86, 490-500 | | 7 |
| 82 | Alteration of type II regulatory subunit of cAMP-dependent protein kinase in human cisplatin-resistant cells as a basis of collateral sensitivity to 8-chloro-cAMP. <i>Japanese Journal of Cancer Research</i> , 1992 , 83, 754-60 | | 7 |
| 81 | Lack of correlation between interferon levels induced by polyribonucleotides and their antimetastatic effect. <i>Oncology</i> , 1990 , 47, 251-6 | 3.6 | 7 |

| | | | |
|----|---|-----|---|
| 80 | Detection of proteins that recognize platinum-modified DNA using gel mobility shift assay. <i>Japanese Journal of Cancer Research</i> , 1990 , 81, 1210-3 | | 7 |
| 79 | In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay. <i>Investigational New Drugs</i> , 1987 , 5, 353-9 | 4.3 | 7 |
| 78 | Drug induced interstitial lung disease in oncology phase I trials. <i>Cancer Science</i> , 2016 , 107, 1830-1836 | 6.9 | 7 |
| 77 | Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. <i>Cancer Science</i> , 2018 , 109, 207-214 | 6.9 | 7 |
| 76 | MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 596-605 | 6.1 | 6 |
| 75 | Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. <i>Drug Safety</i> , 2020 , 43, 233-242 | 5.1 | 6 |
| 74 | Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. <i>Targeted Oncology</i> , 2019 , 14, 647-656 | 5 | 6 |
| 73 | Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 491-492 | 6.1 | 6 |
| 72 | The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 319-24 | 2.8 | 6 |
| 71 | Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 699-706 | 2.8 | 6 |
| 70 | Inhibition of colony formation of drug-resistant human tumor cell lines by combinations of interleukin-2-activated killer cells and antitumor drugs. <i>Japanese Journal of Cancer Research</i> , 1989 , 80, 265-70 | | 6 |
| 69 | Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44 years. <i>Breast Cancer</i> , 2019 , 26, 386-396 | 3.4 | 6 |
| 68 | Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. <i>BMC Cancer</i> , 2020 , 20, 325 | 4.8 | 6 |
| 67 | A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin. <i>Anti-Cancer Drugs</i> , 2018 , 29, 97-101 | 2.4 | 6 |
| 66 | Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. <i>Translational Oncology</i> , 2019 , 12, 1386-1394 | 4.9 | 5 |
| 65 | Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: case report. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 456-9 | 2.8 | 5 |
| 64 | Reply to V. Fusco et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e523-e524 | 2.2 | 5 |
| 63 | Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate. <i>International Journal of Clinical Oncology</i> , 2008 , 13, 555-8 | 4.2 | 5 |

| | | | |
|----|--|------|---|
| 62 | Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008 , 134, 389-95 | 4.9 | 5 |
| 61 | Serial measurement of sister chromatid exchanges in the peripheral lymphocytes of patients with lung cancer receiving chemotherapy in relation to bone marrow toxicity. <i>Japanese Journal of Cancer Research</i> , 1989 , 80, 783-6 | | 5 |
| 60 | Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. <i>JCO Oncology Practice</i> , 2021 , 17, e416-e425 | 2.3 | 5 |
| 59 | The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1850-1855 | 3.5 | 4 |
| 58 | Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on F-fluorodeoxyglucose positron emission tomography/computed tomography. <i>Medical Oncology</i> , 2019 , 36, 58 | 3.7 | 4 |
| 57 | Genomics, health care, and society. <i>New England Journal of Medicine</i> , 2011 , 365, 2339 | 59.2 | 4 |
| 56 | Atypical tumor-stromal fibroblasts in invasive ductal carcinomas of the breast treated with neoadjuvant therapy. <i>Human Pathology</i> , 2011 , 42, 998-1006 | 3.7 | 4 |
| 55 | Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma. <i>Oncology Reports</i> , 2008 , | 3.5 | 4 |
| 54 | Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2007 , 103, 313-8 | 4.4 | 4 |
| 53 | The next step to approaching central nervous system metastasis in HER-2-positive metastatic breast cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006 , 2, 6-8 | 1.9 | 4 |
| 52 | Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. <i>Case Reports in Oncological Medicine</i> , 2020 , 2020, 2518383 | 0.9 | 3 |
| 51 | Toward global standardization of conducting fair investigations of allegations of research misconduct. <i>Accountability in Research</i> , 2020 , 27, 327-346 | 1.9 | 3 |
| 50 | Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy. <i>Internal Medicine</i> , 2017 , 56, 2879-2882 | 1.1 | 3 |
| 49 | Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. <i>Therapeutic Innovation and Regulatory Science</i> , 2018 , 52, 334-338 | 1.2 | 3 |
| 48 | Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. <i>Investigational New Drugs</i> , 2018 , 36, 151-155 | 4.3 | 3 |
| 47 | Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site. <i>BMC Cancer</i> , 2018 , 18, 176 | 4.8 | 3 |
| 46 | Second-line chemotherapy in patients with primary unknown cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 1185-91 | 4.9 | 3 |
| 45 | De-identification procedure and sample quality of the post-clinical test samples at the bio-repository of the National Cancer Center Hospital (NCCH) in Tokyo. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 295-8 | 2.8 | 3 |

| | | | |
|----|--|-----|---|
| 44 | Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection. <i>Oncology</i> , 2012 , 82, 228-33 | 3.6 | 3 |
| 43 | Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging. <i>Scientific Reports</i> , 2020 , 10, 15535 | 4.9 | 3 |
| 42 | A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 803-809 | 6.1 | 2 |
| 41 | Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. <i>Oncology</i> , 2020 , 98, 699-705 | 3.6 | 2 |
| 40 | Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDAR perspective. <i>Journal of Artificial Organs</i> , 2020 , 23, 203-206 | 1.8 | 2 |
| 39 | Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen. <i>Cancer Science</i> , 2012 , 103, 491-6 | 6.9 | 2 |
| 38 | A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. <i>Medical Oncology</i> , 2011 , 28, 434-40 | 3.7 | 2 |
| 37 | Effectiveness of MAID Therapy against Metastatic Malignant Phylloides Tumors and Stromal Sarcoma of the Breast. <i>Breast Care</i> , 2006 , 1, 194-197 | 2.4 | 2 |
| 36 | Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. <i>International Journal of Clinical Oncology</i> , 2005 , 10, 272-5 | 4.2 | 2 |
| 35 | MASTER KEY project: A basket/umbrella trial for rare cancers in Japan.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS2598-TPS2598 | 2.2 | 2 |
| 34 | Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal. <i>PLoS ONE</i> , 2012 , 7, e44393 | 3.7 | 2 |
| 33 | The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site. <i>Internal Medicine</i> , 2019 , 58, 1423-1428 | 1.1 | 2 |
| 32 | III. Advanced Medical Care B and Patient-proposed Health Services. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2016 , 105, 2336-2345 | 0 | 2 |
| 31 | Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. <i>Oncologist</i> , 2019 , 24, 266-272 | 5.7 | 2 |
| 30 | BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 323-329 | 4.4 | 2 |
| 29 | Back with a vengeance: microvascular tumor embolism. <i>American Journal of Medicine</i> , 2015 , 128, 834-6 | 2.4 | 1 |
| 28 | The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study. <i>Breast Cancer</i> , 2016 , 23, 797-806 | 3.4 | 1 |
| 27 | Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 275-283 | 3.5 | 1 |

| | | | |
|----|---|-----|---|
| 26 | Do investigators show selection biases when enrolling patients in phase I oncology registration trials?. <i>Journal of Geriatric Oncology</i> , 2011 , 2, 25-30 | 3.6 | 1 |
| 25 | Influence of suboptimal treatment in patients with mediastinal primary nonseminomatous germ cell tumors. <i>Oncology</i> , 2010 , 78, 34-9 | 3.6 | 1 |
| 24 | Reply to M.S. Apro. <i>Journal of Clinical Oncology</i> , 2011 , 29, e421-e423 | 2.2 | 1 |
| 23 | Personalized systemic treatment for breast cancer patients: is it a reality?. <i>Breast Cancer</i> , 2008 , 15, 141-4 | 3.4 | 1 |
| 22 | Re: Insulinlike growth factor 1 receptor: predictive factor in breast cancer patients treated with trastuzumab?. <i>Human Pathology</i> , 2005 , 36, 449-449 | 3.7 | 1 |
| 21 | The Role of DNA-Microarray in Translational Cancer Research. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2005 , 3, 201-216 | | 1 |
| 20 | Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers.. <i>Frontiers in Oncology</i> , 2021 , 11, 7325-5 | 2.5 | 1 |
| 19 | A descriptive analysis of post-chemotherapy development of interstitial lung disease using spontaneous reporting data in Japan. <i>Current Drug Safety</i> , 2014 , 9, 220-6 | 1.4 | 1 |
| 18 | Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer. <i>Oncology Letters</i> , 2020 , 20, 336 | 2.6 | 1 |
| 17 | Breast Cancer Stem Cell: Translating to the Clinic 2012 , 249-257 | | 1 |
| 16 | Rare cancers in Japan: definition, clinical features and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 970-975 | 2.8 | 1 |
| 15 | No-fault compensation schemes for COVID-19 medical products. <i>Lancet, The</i> , 2021 , 397, 1707-1708 | 4.0 | 1 |
| 14 | Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. <i>Lung Cancer</i> , 2019 , 128, 20-25 | 5.9 | 1 |
| 13 | Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. <i>Breast Cancer</i> , 2019 , 26, 39-46 | 3.4 | 0 |
| 12 | Weekly Administration of Paclitaxel and Carboplatin in the Treatment of Advanced Ovarian or Peritoneal Cancers With Poor Performance Status. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2010 , 3, 47-51 | | 0 |
| 11 | HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix. <i>Oncology Letters</i> , 2020 , 20, 38 | 2.6 | 0 |
| 10 | Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. <i>Clinical and Translational Science</i> , 2021 , 14, 1015-1025 | 4.9 | 0 |
| 9 | Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1182-1185 | 6.1 | 0 |

| | | |
|---|---|-----|
| 8 | The Incidence and Severity of Paclitaxel-induced Peripheral Neuropathy in Patients with Ovarian Cancer: a Retrospective Study. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2017 , 43, 252-259 | 0.1 |
| 7 | Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010 , 6, 248-50 | 1.9 |
| 6 | Do Patients With Platinum-Resistant Epithelial Ovarian Cancer Benefit From Second-line Chemotherapy?. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2010 , 3, 36-40 | |
| 5 | Outpatient management of low-risk febrile patients on paclitaxel and carboplatin for ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2009 , 105, 261-2 | 4 |
| 4 | Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers. <i>BMC Cancer</i> , 2021 , 21, 1131 | 4.8 |
| 3 | Issues in the investigator-initiated registration-directed clinical trials. <i>Drug Delivery System</i> , 2004 , 19, 453-460 | 0 |
| 2 | Clinical features and the result of treatment for brain metastases in advanced non-small cell lung cancer.. <i>Japanese Journal of Lung Cancer</i> , 1989 , 29, 649-655 | 0.1 |
| 1 | PMDAR efforts to promote medical innovation in the coronavirus pandemic. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2022 , 95, 1-SL04 | 0 |